Palvella Therapeutics, Inc. (NASDAQ:PVLA) Sees Significant Increase in Short Interest

Palvella Therapeutics, Inc. (NASDAQ:PVLA) was the recipient of a significant increase in short interest during the month of December. As of December 31st, there was short interest totaling 1,326,830 shares, an increase of 60.9% from the December 15th total of 824,522 shares. Based on an average trading volume of 327,392 shares, the short-interest ratio is currently 4.1 days. Approximately 14.1% of the company’s stock are sold short. Approximately 14.1% of the company’s stock are sold short. Based on an average trading volume of 327,392 shares, the short-interest ratio is currently 4.1 days.

Palvella Therapeutics Stock Down 4.1%

NASDAQ PVLA opened at $99.73 on Friday. The company has a 50-day moving average price of $96.06 and a 200-day moving average price of $67.95. Palvella Therapeutics has a 52 week low of $12.10 and a 52 week high of $114.69. The firm has a market capitalization of $1.18 billion, a P/E ratio of -37.92 and a beta of -0.16.

Palvella Therapeutics (NASDAQ:PVLA) last announced its earnings results on Monday, November 10th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.18). As a group, equities research analysts anticipate that Palvella Therapeutics will post -3.69 EPS for the current year.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Stifel Nicolaus upped their target price on shares of Palvella Therapeutics from $87.00 to $145.00 and gave the stock a “buy” rating in a research note on Monday, November 24th. Craig Hallum assumed coverage on Palvella Therapeutics in a report on Thursday, December 4th. They set a “buy” rating and a $175.00 price target on the stock. Canaccord Genuity Group raised their price target on shares of Palvella Therapeutics from $148.00 to $204.00 and gave the company a “buy” rating in a report on Tuesday, December 16th. Truist Financial boosted their price objective on shares of Palvella Therapeutics from $105.00 to $190.00 and gave the company a “buy” rating in a report on Monday, December 15th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Palvella Therapeutics in a research report on Monday, December 29th. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $158.69.

Insider Buying and Selling at Palvella Therapeutics

In other news, COO Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $96.47, for a total value of $415,013.94. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 20.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Palvella Therapeutics

Institutional investors have recently bought and sold shares of the stock. SG Americas Securities LLC bought a new stake in Palvella Therapeutics during the fourth quarter valued at about $281,000. JPMorgan Chase & Co. grew its stake in shares of Palvella Therapeutics by 33.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 4,338 shares of the company’s stock valued at $272,000 after acquiring an additional 1,093 shares during the period. Summit Partners Public Asset Management LLC bought a new position in shares of Palvella Therapeutics during the 3rd quarter valued at approximately $2,188,000. Mariner LLC purchased a new stake in Palvella Therapeutics in the 3rd quarter worth approximately $1,299,000. Finally, Fred Alger Management LLC raised its stake in Palvella Therapeutics by 1,279.1% during the 3rd quarter. Fred Alger Management LLC now owns 186,751 shares of the company’s stock worth $11,707,000 after acquiring an additional 173,209 shares during the period. 40.11% of the stock is owned by institutional investors.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.